Atherosclerosis Drugs Market

Atherosclerosis Drugs Market Analysis by Anti-platelet Medications, Cholesterol-lowering Medications, Beta Blockers, ACE Inhibitors, Calcium Channel Blockers, and Diuretics from 2023 to 2033

Analysis of Atherosclerosis Drugs Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Table of Content

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

            4.3.1.1. Increase in Prevalence of Atherosclerosis & Cardiovascular Diseases

            4.3.1.2. Development of New Treatments

            4.3.1.3. Rising Awareness about Cardiovascular Diseases

        4.3.2. Restraints

            4.3.2.1. Availability of Generic Products

            4.3.2.2. Low Diagnostic Rate

        4.3.3. Opportunities

    4.4. Global Market Analysis and Forecast, 2023–2033

5. Market Outlook

    5.1. Clinical Trial Pipeline Analysis

    5.2. Disease Prevalence & Incidence Rate globally with key countries

    5.3. Brand Analysis

6. Global Market Analysis and Forecast, By Drug Class

    6.1. Introduction & Definition

        6.1.1. Key Findings / Developments

    6.2. Global Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

        6.2.1. Anti-platelet Medications

        6.2.2. Cholesterol Lowering Medications

        6.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

        6.2.4. Beta Blockers

        6.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

        6.2.6. Calcium Channel Blockers

        6.2.7. Diuretics

        6.2.8. Others

    6.3. Global Market Attractiveness, by Drug Class

7. Global Market Analysis and Forecast, By Distribution Channel

    7.1. Introduction & Definition

        7.1.1. Key Findings / Developments

    7.2. Global Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

        7.2.1. Retail Pharmacies

        7.2.2. Hospital Pharmacies

        7.2.3. Online Pharmacies

    7.3. Global Market Attractiveness, by Distribution Channel

8. Global Market Analysis and Forecast, By Region

    8.1. Key Findings

    8.2. Global Market Revenue (US$ Mn) Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Global Market Attractiveness, by region

9. North America Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. North America Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

        9.2.1. Anti-platelet Medications

        9.2.2. Cholesterol Lowering Medications

        9.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

        9.2.4. Beta Blockers

        9.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

        9.2.6. Calcium Channel Blockers

        9.2.7. Diuretics

        9.2.8. Others

    9.3. North America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

        9.3.1. Retail Pharmacies

        9.3.2. Hospital Pharmacies

        9.3.3. Online Pharmacies

    9.4. North America Market Revenue (US$ Mn) Forecast, by Country, 2023–2033

        9.4.1. U.S.

        9.4.2. Canada

    9.5. North America Market Attractiveness

        9.5.1. By Drug Type

        9.5.2. By Distribution Channel

        9.5.3. By Country

10. Europe Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Europe Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

        10.2.1. Anti-platelet Medications

        10.2.2. Cholesterol Lowering Medications

        10.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

        10.2.4. Beta Blockers

        10.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

        10.2.6. Calcium Channel Blockers

        10.2.7. Diuretics

        10.2.8. Others

    10.3. Europe Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

        10.3.1. Retail Pharmacies

        10.3.2. Hospital Pharmacies

        10.3.3. Online Pharmacies

    10.4. Europe Market Revenue (US$ Mn) Forecast, by Country Sub/region, 2023–2033

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Europe Market Attractiveness

        10.5.1. By Drug Type

        10.5.2. By Distribution Channel

        10.5.3. By Country/Sub-region

11. Asia Pacific Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Asia Pacific Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

        11.2.1. Anti-platelet Medications

        11.2.2. Cholesterol lowering medications

        11.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

        11.2.4. Beta blockers

        11.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

        11.2.6. Calcium Channel Blockers

        11.2.7. Diuretics

        11.2.8. Others

    11.3. Asia Pacific Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

        11.3.1. Retail Pharmacies

        11.3.2. Hospital Pharmacies

        11.3.3. Online Pharmacies

    11.4. Asia Pacific Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Asia Pacific Market Attractiveness

        11.5.1. By Drug Type

        11.5.2. By Distribution Channel

        11.5.3. By Country/Sub-region

12. Latin America Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Latin America Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

        12.2.1. Anti-platelet Medications

        12.2.2. Cholesterol Lowering Medications

        12.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

        12.2.4. Beta blockers

        12.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

        12.2.6. Calcium Channel Blockers

        12.2.7. Diuretics

        12.2.8. Others

    12.3. Latin America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

        12.3.1. Retail Pharmacies

        12.3.2. Hospital Pharmacies

        12.3.3. Online Pharmacies

    12.4. Latin America Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Latin America Market Attractiveness

        12.5.1. By Drug Type

        12.5.2. By Distribution Channel

        12.5.3. By Country/Sub-region

13. Middle East & Africa Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Middle East & Africa Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

        13.2.1. Anti-platelet medications

        13.2.2. Cholesterol Lowering Medications

        13.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

        13.2.4. Beta blockers

        13.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

        13.2.6. Calcium Channel Blockers

        13.2.7. Diuretics

        13.2.8. Others

    13.3. Middle East & Africa Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

        13.3.1. Retail Pharmacies

        13.3.2. Hospital Pharmacies

        13.3.3. Online Pharmacies

    13.4. Middle East & Africa Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

        13.4.1. GCC

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Middle East & Africa Market Attractiveness

        13.5.1. By Drug Type

        13.5.2. By Distribution Channel

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player – Competition Matrix (By Tier and Size of companies)

    14.2. Key Company’s Market Ranking Analysis

    14.3. Company Profiles

        14.3.1. GlaxoSmithKline Plc

            14.3.1.1. Company Overview

            14.3.1.2. Company Financials

            14.3.1.3. Growth Strategies

            14.3.1.4. SWOT Analysis

        14.3.2. Sanofi

            14.3.2.1. Company Overview

            14.3.2.2. Company Financials

            14.3.2.3. Growth Strategies

            14.3.2.4. SWOT Analysis

        14.3.3. Hoffmann-La Roche Ltd

            14.3.3.1. Company Overview

            14.3.3.2. Company Financials

            14.3.3.3. Growth Strategies

            14.3.3.4. SWOT Analysis

        14.3.4. Bayer AG

            14.3.4.1. Company Overview

            14.3.4.2. Company Financials

            14.3.4.3. Growth Strategies

            14.3.4.4. SWOT Analysis

        14.3.5. Novartis AG

            14.3.5.1. Company Overview

            14.3.5.2. Company Financials

            14.3.5.3. Growth Strategies

            14.3.5.4. SWOT Analysis

        14.3.6. Merck & Co., Inc. (Merck Sharp & Dohme Corp)

            14.3.6.1. Company Overview

            14.3.6.2. Company Financials

            14.3.6.3. Growth Strategies

            14.3.6.4. SWOT Analysis

        14.3.7. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

            14.3.7.1. Company Overview

            14.3.7.2. Company Financials

            14.3.7.3. Growth Strategies

            14.3.7.4. SWOT Analysis

        14.3.8. Mylan N.V.

            14.3.8.1. Company Overview

            14.3.8.2. Company Financials

            14.3.8.3. Growth Strategies

            14.3.8.4. SWOT Analysis

        14.3.9. Amgen Inc.

            14.3.9.1. Company Overview

            14.3.9.2. Company Financials

            14.3.9.3. Growth Strategies

            14.3.9.4. SWOT Analysis

        14.3.10. Pfizer, Inc.

            14.3.10.1. Company Overview

            14.3.10.2. Company Financials

            14.3.10.3. Growth Strategies

            14.3.10.4. SWOT Analysis

Don't Need a Global Report?

save 40%! on Country & Region specific reports

List Of Table

Table 01: Atherosclerosis Pipeline Analysis

Table 02: Atherosclerosis Pipeline Analysis

Table 03: Global Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

Table 04: Global Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 05: Global Market Revenue (US$ Mn) Forecast, by Region, 2023–2033

Table 06: North America Market Revenue (US$ Mn) Forecast, by Drug Class 2023–2033

Table 07: North America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 08: North America Market Revenue (US$ Mn) Forecast, by Country, 2023–2033

Table 09: Europe Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

Table 10: Europe Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 11: Europe Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

Table 12: Asia Pacific Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

Table 13: Asia Pacific Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 14: Asia Pacific Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

Table 15: Latin America Market Revenue (US$ Mn) Forecast, by Drug Class 2023–2033

Table 16: Latin America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 17: Latin America Market Revenue (US$ Mn) Forecast, by Country / Sub-region, 2023–2033

Table 18: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

Table 19: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 20: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

List Of Figures

Figure 01: Global Market Revenue (US$ Mn) and Distribution (%), by Region, 2023 and 2033

Figure 02: Global Market Revenue (US$ Mn), by Drug Class, 2023

Figure 03: Global Market Revenue Share Analysis, by Drug Class, 2023

Figure 04: Market Overview

Figure 05: Global Market Revenue Share, by Drug Class, 2023

Figure 06: Global Market Revenue Share, by Distribution Channel, 2023

Figure 07: Global Market Revenue Share, by Region, 2023

Figure 08: Global Market Revenue (US$ Mn) Forecast, 2023–2033

Figure 09: Global Market Revenue Share Analysis, by Drug Class, 2023 and 2033

Figure 10: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anti-platelet Medications, 2023–2033

Figure 11: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Cholesterol Lowering Medications, 2023–2033

Figure 12: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Fibric Acid and Omega-3 Fatty Acid Derivatives, 2023–2033

Figure 13: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Beta Blockers, 2023–2033

Figure 14: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Angiotensin-converting Enzyme (ACE) Inhibitors, 2023–2033

Figure 15: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Calcium Channel Blockers, 2023–2033

Figure 16: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Diuretics, 2023–2033

Figure 17: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2023–2033

Figure 18: Global Market Attractiveness Analysis, by Drug Class, 2023–2033

Figure 19: Global Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033

Figure 20: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth(%) Projection, by Retail Pharmacies, 2023–2033

Figure 21: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2023–2033

Figure 22: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2023–2033

Figure 23: Global Market Attractiveness Analysis, by Distribution Channel, 2023–2033

Figure 24: Global Market Revenue Share Analysis, by Region, 2023 and 2033

Figure 25: Global Market Attractiveness Analysis, by Region, 2023–2033

Figure 26: North America Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033

Figure 27: North America Market Revenue Share Analysis, by Drug Class, 2023 and 2033

Figure 28: North America Market Attractiveness Analysis, by Drug Class, 2023–2033

Figure 29: North America Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033

Figure 30: North America Market Attractiveness Analysis, by Distribution Channel, 2023 -2033

Figure 31: North America Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033

Figure 32: North America Market Attractiveness Analysis, by Country/Sub-region, 2023–2033

Figure 33: Europe Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033

Figure 34: Europe Market Revenue Share Analysis, by Drug Class, 2023 and 2033

Figure 35: Europe Market Attractiveness Analysis, by Drug Class, 2023–2033

Figure 36: Europe Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033

Figure 37: Europe Market Attractiveness Analysis, by Distribution Channel, 2023–2033

Figure 38: Europe Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033

Figure 39: Europe Market Attractiveness Analysis, by Country/Sub-region, 2023–2033

Figure 40: Asia Pacific Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033

Figure 41: Asia Pacific Market Revenue Share Analysis, by Drug Class, 2023 and 2033

Figure 42: Asia Pacific Market Attractiveness Analysis, by Drug Class, 2023–2033

Figure 43: Asia Pacific Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033

Figure 44: Asia Pacific Market Attractiveness Analysis, by Distribution Channel, 2023 -2033

Figure 45: Asia Pacific Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033

Figure 46: Asia Pacific Market Attractiveness Analysis, by Country/Sub-region, 2023–2033

Figure 47: Latin America Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033

Figure 48: Latin America Market Revenue Share Analysis, by Drug Class, 2023 and 2033

Figure 49: Latin America Market Attractiveness Analysis, by Drug Class, 2023–2033

Figure 50: Latin America Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033

Figure 51: Latin America Market Attractiveness Analysis, by Distribution Channel, 2023 -2033

Figure 52: Latin America Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033

Figure 53: Latin America Market Attractiveness Analysis, by Country/Sub-region, 2023–2033

Figure 54: Middle East & Africa Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033

Figure 55: Middle East & Africa Market Revenue Share Analysis, by Drug Class, 2023 and 2033

Figure 56: Middle East & Africa Market Attractiveness Analysis, by Drug Class, 2023–2033

Figure 57: Middle East & Africa Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033

Figure 58: Middle East & Africa Market Attractiveness Analysis, by Distribution Channel, 2023 -2033

Figure 59: Middle East & Africa Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033

Figure 60: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region, 2023–2033

Figure 61: Market Position Analysis, 2023, by Tier and Size of the Company

Figure 62: GlaxoSmithKline plc (US$ Mn) and Y-o-Y Growth (%), 2018–2023

Figure 63: GlaxoSmithKline plc Breakdown of Net Sales (%), by Region/Country, 2023

Figure 64: GlaxoSmithKline plc Revenue Breakdown of Net Sales (%), by Business segment, 2023

Figure 65: GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023

Figure 66: Sanofi (US$ Mn) and Y-o-Y Growth (%), 2018–2023

Figure 65: GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023

Figure 68: Sanofi Revenue Breakdown of Net Sales (%), by Pharmaceutical Business segment, 2023

Figure 69: Sanofi R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2023–2023

Figure 70: F. Hoffmann-La Roche Ltd Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2023

Figure 71: F. Hoffmann-La Roche Ltd Breakdown of Net Sales (%), by Region, 2023

Figure 72: F. Hoffmann-La Roche Ltd Breakdown of Net Sales (%), by Pharmaceutical Division, 2023

Figure 73: F. Hoffmann-La Roche Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023

Figure 74: Bayer AG, Pharmaceutical Revenue (US$ Mn) and Y-o-Y Growth (%), 2023–2023

Figure 75: Bayer AG Breakdown of Net Sales (%), by Region, 2023

Figure 76: Bayer AG Revenue Breakdown of Net Sales (%), by Business segment, 2023

Figure 77: Bayer AG, pharmaceutical segment R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023

Figure 78: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2023

Figure 79: Novartis AG Breakdown of Net Sales (%) of Innovative Medicines Business Segment, by Region/Country, 2023

Figure 80: Novartis AG Revenue Breakdown of Net Sales (%), by Innovative Medicines Segment, 2023

Figure 81: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023

Figure 82: Merck & Co., Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2023

Figure 83: Merck & Co., Inc. Breakdown of Net Sales (%), by Region/Country, 2023

Figure 84: Merck & Co., Inc. Revenue Breakdown of Net Sales (%), by Segment, 2023

Figure 85: Merck & Co., Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023

Figure 86: Johnson & Johnson Pharmaceutical Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2023–2023

Figure 87: Johnson & Johnson Breakdown of Net Sales (%), of Pharmaceutical Segment by Region/Country, 2023

Figure 88: Johnson & Johnson Revenue Breakdown of Net Sales (%), by Pharmaceutical Segment, 2023

Figure 89: Johnson & Johnson, Pharmaceutical Segment R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2023–2023

Figure 90: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2023

Figure 91: Mylan N.V. R&D Expenses (US$ Mn), 2023–2023

Figure 92: Mylan N.V. Breakdown of Net Sales, by Region, 2023

Figure 93: Amgen, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2023

Figure 94: Amgen, Inc. Breakdown of Net Sales (%), by Region/Country, 2023

Figure 95: Amgen Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), by Segment 2014–2023

Figure 96: Pfizer, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2023

Figure 97: Pfizer, Inc. Breakdown of Net Sales, by Geography, 2023

Figure 98: Pfizer, Inc. Breakdown of Net Sales, by Business Segment (%), 2023

Figure 99: Pfizer, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Atherosclerosis Drugs Market

Schedule a Call